Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie kliniczne stent-graftu Treovance'a u pacjentów z tętniakami aorty brzusznej

10 listopada 2026 zaktualizowane przez: Bolton Medical

Badanie kliniczne II fazy dotyczące bezpieczeństwa i działania stent-graftu Treovance'a z systemem wprowadzającym Navitel u pacjentów z tętniakami aorty brzusznej podnerkowej

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. Upon completion of enrollment of150 subjects, an additional 50 subjects may be treated with the Treovance Stent-Graft at the 30 investigative sites participating in the trial. These additional subjects will follow the same study schedule, and data from these patients may be used to supplement the pivotal trial data. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted. Subjects with fracture(s) confirmed by the Core Lab within the first 5 years will be followed for an additional 5 years, for a total of 10 years post-implantation.

The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S.

There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms:

  • Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant
  • Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days

Secondary objectives involve assessment of major device-related events and major morbidity.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

158

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35294
        • University of Alabama-Birmingham
    • Arizona
      • Phoenix, Arizona, Stany Zjednoczone, 85006
        • Arizona Heart Institute
    • Connecticut
      • Danbury, Connecticut, Stany Zjednoczone, 06810
        • Danbury Hospital
    • Florida
      • Boca Raton, Florida, Stany Zjednoczone, 33486
        • Lynn Heart and Vascular Institute
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30342
        • Northside Hospital Heart & Vascular Institute
    • Illinois
      • Champaign, Illinois, Stany Zjednoczone, 61820
        • Presence Medical Center -- Christie Clinic
      • Chicago, Illinois, Stany Zjednoczone, 60637
        • University of Chicago
      • Rockford, Illinois, Stany Zjednoczone, 61103
        • Affiliated Surgeons of Rockford Memorial Hospital
    • Iowa
      • Iowa City, Iowa, Stany Zjednoczone, 52242
        • University of Iowa Hospital and Clinic
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Stany Zjednoczone, 02111
        • Tufts University Medical Center
      • Worcester, Massachusetts, Stany Zjednoczone, 01655
        • University of Massachusetts
    • Minnesota
      • Rochester, Minnesota, Stany Zjednoczone, 55905
        • Mayo Clinic
    • New York
      • Albany, New York, Stany Zjednoczone, 12205
        • Community Care (previously Albany Medical Center)
      • Buffalo, New York, Stany Zjednoczone, 14203
        • Buffalo General Medical Center
      • New York, New York, Stany Zjednoczone, 10029
        • Mount Sinai Medical Center
      • Rochester, New York, Stany Zjednoczone, 14623
        • University of Rochester -- Strong Memorial Hospital
      • Stony Brook, New York, Stany Zjednoczone, 11794-8191
        • Stony Brook Medical Center
    • North Carolina
      • Asheville, North Carolina, Stany Zjednoczone, 28801
        • Mission Hospital
      • Greenville, North Carolina, Stany Zjednoczone, 27834
        • East Carolina University / Pitt County Memorial Hospital
    • Ohio
      • Cleveland, Ohio, Stany Zjednoczone, 44195
        • Cleveland Clinic Foundation
      • Columbus, Ohio, Stany Zjednoczone, 43210
        • The Ohio State University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19140
        • Temple University School of Medicine
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
        • University of Pittsburgh Medical Center
      • York, Pennsylvania, Stany Zjednoczone, 17403
        • York Hospital
    • Rhode Island
      • Providence, Rhode Island, Stany Zjednoczone, 02905
        • Rhode Island Hospital
    • South Dakota
      • Sioux Falls, South Dakota, Stany Zjednoczone, 57117
        • Sanford University of South Dakota Medical Center
      • Sioux Falls, South Dakota, Stany Zjednoczone, 51108
        • North Central Heart (Avera Heart Hospital)
    • Virginia
      • Norfolk, Virginia, Stany Zjednoczone, 23507
        • Sentara Vascular Specialists

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 85 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Subject must be between the ages of 18 and 85
  2. Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement, by CT with contrast performed within 4 months of planned implant procedure
  3. Subject must have an infrarenal AAA that i. is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or ii. has increased in diameter by 0.5 cm in the last 6 months
  4. Subject must have i. infrarenal landing neck length of 10 mm or greater and an angle of less than 60 degrees relative to the long axis of the aneurysm (centerline at lowest renal to centerline at bifurcation) and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 17 mm -32 mm, or ii. infrarenal landing neck length of 15 mm or greater and an angle of between 60 and 75 degrees relative to the long axis of the aneurysm and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 16 mm-30 mm
  5. Subject's infrarenal landing neck must meet the vessel size requirements specified in the instructions for use (IFU) for the corresponding devices
  6. Subject must have lowest renal artery at least 9 cm from the aortic bifurcation
  7. Subject must have a distal iliac landing neck with i. an inside diameter of 8 mm - 13 mm and a length of at least 10 mm, or ii. an inside diameter of >13 mm - 20 mm and a length of at least 15 mm
  8. Subject's distal iliac landing neck must meet the vessel size requirements specified for the corresponding devices in the IFU
  9. Subject must have a total treatment length of at least 13 cm
  10. Subject must have a distal aortic diameter above the iliac bifurcation equal to or greater than 70% of the sum of the selected leg graft diameters that will pass through the same
  11. Subject must be willing and able to comply with 1-month, 6-month, and 12-month follow-up visits, as well as annual visits out to 5 years
  12. Subject must have adequate renal function to tolerate required follow-up contrast-enhanced CTs
  13. Subject must have adequate vascular access (e.g., patent iliac or femoral arteries) for introduction of the Navitel Delivery System, which is 18F (6 mm) or 19F (6.3 mm) outer diameter based on size of device used. Alternatively, subject's anatomy is suitable for creation of an iliac conduit.
  14. Subject or Legally Authorized Representative (LAR) must agree to sign Informed Consent Form

Exclusion Criteria:

  1. Subject is pregnant or lactating
  2. Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)
  3. Subject has a patent inferior mesenteric artery that cannot be sacrificed and an occluded or stenotic celiac and/or superior mesenteric artery
  4. Implant procedure as planned does not allow for at least one patent hypogastric artery left intact, unless both are occluded on pre-op imaging
  5. Subject has a lesion that cannot be crossed by a guide wire
  6. Proximal neck cannot increase by more than 10% over 15mm or more than 7% over 10mm; i.e., no trapezoidal necks
  7. Subject has severe untreated coronary artery disease and/or unstable angina, significant areas of myocardium at risk (based on coronary angiogram or radionuclide scans), left ventricular ejection fraction < 20%, or recent diagnosis of Congestive Heart Failure (CHF)
  8. Subject has had a stroke or myocardial infarction within 6 months of the planned treatment date
  9. Subject has chronic obstructive pulmonary disease requiring routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use)
  10. Subject has an active systemic infection or is suspected of having an active systemic infection (e.g.,AIDS/HIV, sepsis)
  11. Subject is morbidly obese (more than 100% over the ideal body weight or as defined by institutional standards) or has other clinical conditions that severely compromise or impair x-ray visualization of the aorta
  12. Subject has connective tissue disease (e.g., Marfan's syndrome)
  13. Subject has a mycotic aneurysm
  14. Subject has significant or circumferential calcification or mural thrombus in the proximal aortic neck
  15. Subject has significant or circumferential calcification or mural thrombus in the distal iliac landing zone
  16. Subject has significant or circumferential calcification or mural thrombus within the treatment length, which may adversely impact device patency
  17. Subject has a blood coagulation disorder or bleeding diathesis, the treatment for which cannot be suspended pre- and post-repair
  18. Subject is in acute or chronic renal failure (creatinine > 2.5 mg/dL) unless subject is stable on dialysis
  19. Subject has less than two-year life expectancy as evidenced by factors prohibiting major medical intervention (e.g., presence of malignancy, severe cardiopulmonary disease, etc.)
  20. Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure
  21. Subject is confronted with other medical, social or psychological issues that the investigator believes may interfere with study treatment or follow-up. These reasons must be documented. An example may include adherence to a theological or personal doctrine with aversion or opposition to blood transfusion.
  22. Subject has had a prior AAA repair (endovascular or surgical)
  23. Subject has an untreatable allergy or sensitivity to contrast media, nitinol/nickel, or polyester
  24. Subject has undergone other major surgical or medical intervention within 45 days of the planned procedure or is planning to undergo other major surgical or medical intervention within 45 days post implantation (e.g., Coronary Artery Bypass Graft (CABG), organ transplantation, renal stenting, etc.)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Treovance

Subjects who receive the Treovance stent-graft

Eligible subjects will be implanted with the Treovance Stent-Graft

Inne nazwy:
  • Stent-graft brzuszny Treovance z systemem wprowadzającym Navitel

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Primary Efficacy
Ramy czasowe: 12 months

Successful aneurysm treatment which is a composite of the following: Technical success at the conclusion of the procedure; absence of aneurysm enlargement; absence of device-related complications (e.g., fracture, conversion to open surgical repair, etc.)

12 months
Primary Safety
Ramy czasowe: 30 days

The primary safety endpoint is composite major adverse event (MAE) rate (including myocardial infarction, stroke, respiratory failure, etc.)

30 days

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Secondary Efficancy Endpoint -- Aneurysm-Related Mortality
Ramy czasowe: Annually to 5-years; annually to 10-years (stent-fracture subjects only)

Aneurysm-related mortality at 12 month and annually to 5 years; annually to 10 years for subjects with Core Lab-confirmed fracture(s)

Annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Efficacy Endpoint -- Technical Success
Ramy czasowe: 30 days

Technical success at 30 days confirmed by an imaging modality (e.g. CT)

30 days
Secondary Efficacy Endpoint -- Clinical Utility Measures
Ramy czasowe: Perioperative/Periprocedural

Clinical utility measures (procedure time, time in the intensive care unit, length of hospital stay)

Perioperative/Periprocedural
Secondary Efficacy Endpoint -- Secondary interventions
Ramy czasowe: 30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)

The secondary efficacy endpoint includes the rate of additional procedures performed to correct the original implant

30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Efficacy Endpoint -- Device-Related Events
Ramy czasowe: 30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)

This endpoint includes the rate of events associated with the device.

30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Safety Endpoint -- Individual Rate for Events included in the composite MAE
Ramy czasowe: 30 days, 6 months, annually to 5 years

Secondary safety endpoints will include each individual rate for the adverse events included in the composite MAE at 30 days, 6 months, and annually to 5 years

30 days, 6 months, annually to 5 years
Secondary Safety Endpoint -- Procedure-Related Complications
Ramy czasowe: 30 days, 6 months, annually to 5 years

Procedure-related complications at 30 days, 6 months, 12 months, and annually to 5 years.

30 days, 6 months, annually to 5 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Matthew Eagleton, MD, Cleveland Clinic Foundaton

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

23 listopada 2013

Zakończenie podstawowe (Rzeczywisty)

20 marca 2017

Ukończenie studiów (Rzeczywisty)

22 stycznia 2026

Daty rejestracji na studia

Pierwszy przesłany

6 listopada 2013

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 grudnia 2013

Pierwszy wysłany (Szacowany)

12 grudnia 2013

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • IP-0008-12

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .